top of page
Garlic

E-mail:    ckli@cuhk.edu.hk

Publons: J-8456-2013


Administrative support: Ms Lily Yu 

Telephone (office): (852) 

Professor LI Chi Kong
李志光教授

  • Research Professor, Department of Paediatrics

M.B, BS,MRCP(UK), DCH(London), FHKCPaed, FHKAM(Paed), Diploma in Epidemiology & Applied Statistics (CUHK), FRCPCH(UK), Doctor of Medicine(CUHK)

Clinical Team: Haematology & Oncology (Team Head)


Research Team: Paediatric Haematology & Oncology

©Protected Content

Biography

Dr. CK Li graduated from the University of Hong Kong in 1981. He completed general paediatric training at Hong Kong and then specialised in paediatric Haematology/oncology/BMT, with further training at John Radcliff Hospital, Oxford, and Great Ormond Street Hospital, London in 1986, and Fred Hutchison Cancer Research Centre, Seattle in 1992. Dr. Li joined PWH in 1989 as Senior Medical Officer and became consultant in 1993, and then clinical professor, and currently Research Professor. His main interest is in childhood leukaemia, thalassaemia, stem cell transplant and cellular and gene therapy, palliative care and bioethics. He is the study chair for acute lymphoblastic leukaemia trials in Hong Kong and also local coordinators for several international multicenter studies. He introduced the new treatment methods for Hong Kong children including double unit umbilical cord blood transplantation, MIBG treatment for neuroblastoma, the first local manufactured CAR-T clinical trial, and gene therapy for thalassaemia. Dr. Li also actively involves in the development of paediatric oncology in mainland China. He had been vice-chairman of China Children Cancer Group, and vice-chairman of steering committee for three consecutive multi-center leukaemia studies in China. Internationally he was the Past-President of Asia Continent of International Society of Pediatric Oncology, and currently the Executive Board member of Asia Pediatric Hematology Oncology Group. He has published over 400 peer-reviewed papers, written chapters in 9 books and editor of one book. He also served as editors in medical journals including Frontier Oncology, Medical Ethics and Bioethics.


Research Interests

  • Paediatric Haematology, thalassaemia

  • Leukaemia

  • Stem cell transplantation, cellular and gene therapy


Honorary Appointments

  • Honorary Consultant, Departments of Paediatrics, Prince of Wales Hospital

  • Hong Kong Children’s Hospital


Professional and Public Service

  • Member, Hospital Governing Committee, Queen Elizabeth Hospital, Hospital Authority.

  • Member, Public Complaints Committee, Hospital Authority, Hong Kong.

  • Board Member, Hong Kong Marrow Match Foundation.

  • Board member, Hong Kong Children’s Thalassaemia Foundation

  • Member, International BFM Study Group (Childhood Leukemia )

  • Governor, Children’s Cancer Foundation, Hong Kong.

  • Council member, Hong Kong Red Cross.

  • Member, Barristers Disciplinary Tribunal Panel, Hong Kong.

Selected Publications: (over 300 peer-reviewed papers)

  1. Cheng FWT, Li BS, Lam GKS, Hon KL, Joynt G, Li CK. Management of cytokine release syndrome after chimeric antigen T-cell therapy for paediatric relapsed/refractory acute lymphoblastic leukaemia: a case report.  Hong Kong Medical Journal, 2020; 26:532-534.    

  2. Feng JH, Cheng FWT, Leung AWK, Lee V, Yeung EWM, Lam HC, Cheung J, Lam GSK, Chow TTW, Yan CLS, Li CK.  Upfront consolidation treatment with 131I-mIBG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high-risk neuroblastoma.  Pediatric Investigation, 2020; 4(3):168-177, doi.org/10.1002/ped4.12216 

  3. Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, Zhai X, Liang C, Ju X, Jiang H, Jin R, Wu X, Wang N, Tian X, Pan K, Jiang H, Sun L, Fang Y, Li CK, Hu Q, Yang M, Zhu Y, Zhang H, Li C, Pei D, Jeha S, Yang JJ, Cheng C, Tang J, Zhu X, Pui CH. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2020 Jan 16. doi: 10.1001/jamaoncol.2019.5868.

  4. Zhu Y, Yang R, Cai J, Yu J, Tang Y, Chen Y, Wang N, He H, Wu X, Cheng FWT, Sun L, He Y, Ju X, Tian X, Hu Q, Jin R, Pan K, Fang Y, Zhai X, Jiang H, Li CK. Septicemia after chemotherapy for childhood acute lymphoblastic leukemia in China: A multicenter study CCCG-ALL-2015. Cancer Med, 2020 Jan 28. doi: 10.1002/cam4.2889.

  5. Leung KT, Zhang C, Chan KYY, Li K, Cheung JTK, Ng MHL, Zhang XB, Sit T, Lee WYW, Kang W, To KF, Yu JWS, Man TKF, Wang H, Tsang KS, Cheng FWT, Lam GKS, Chow TW, Leung AWK, Leung TF, Yuen PMP, Ng PC, Li CK.  CD9 blockade suppresses disease progression of high-risk pediatric B-cell precursor acute lymphoblastic leukemia and enhances chemosensitivity.  Leukemia, 2020; 34:709-720. 

  6. Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, Campbell M, Escherich G, Ferster A, Gardner RA, Kotecha RS, Lausen B, Li CK, Locatelli F, Attarbaschi A, Peters C, Rubnitz JE, Silverman LB, Stary J, Szczepanski T, Vora A, Schrappe M, Valsecchi MG. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol. 2019 Sep 1;37(25):2246-2256.

  7. Biondi A, Cario G, De Lorenzo P, Castor A, Conter V, Leoni V, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Attarbaschi A, Li CK, Vora A, Bradtke J, Saha V, Valsecchi MG, Schrappe M.  Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor.  Haematologica. 2019 Jan;104(1):e13-e16.

  8. Lund TC, Ahn KW, Tecca HR, Hilgers MV, Abdel-Azim H, Abraham A, Diaz MA, Badawy SM, Broglie L, Brown V, Dvorak CC, Gonzalez-Vicent M, Hashem H, Hayashi RJ, Jacobsohn DA, Kent MW, Li CK, Margossian SP, Martin PL, Mehta P, Myers K, Olsson R, Page K, Pulsipher MA, Shaw PJ, Smith AR, Triplett BM, Verneris MR, Eapen M.  Outcomes After Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia.  Biol Blood Marrow Transplant. 2019, 25:301-306.

  9. Cui L, Li ZG, Chai YH, Yu J, Gao J, Zhu XF, Jin RM, Shi XD, Zhang LP, Gao YJ, Zhang RD, Zheng HY, Hu SY, Cui YH, Zhu YP, Zou Y, Ng MHL, Xiao Y, Li JH, Zhang YH, He HL, Xian Y, Wang TY, Li CK, Wu MY; Chinese Children Leukemia Group(CCLG). Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China. Am J Hematol. 2018 Apr 20. doi: 10.1002/ajh.25124. 

  10. Biondi A, Gandemer V, De Lorenzo P, Cario G, Campbell M, Castor A, Pieters R, Baruchel A, Vora A, Leoni V, Stary J, Escherich G, Li CK, Cazzaniga G, Cavé H, Bradtke J, Conter V, Saha V, Schrappe M, Grazia Valsecchi M.  Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010):  a prospective, intergroup, open-label, single-arm clinical trial.  Lancet Haematol, 2018 Dec;5(12):e641-e652.


Selected Publications: (over 400 peer-reviewed papers)

1. Nakata K, Cheung YT, Kato M, Nguyen Huong G, Lam CS, Matsuda T, Steliarova-Foucher E, Pritchard-Jones K, Matsumoto K, Yoneda A, Hori H, Nakagawara A, Li CK. Epidemiology of childhood cancer in Asia. eClinicalMedicine. 2025; Nov 4;89:103554. doi:10.1016/j.eclinm.2025.103554. PMID: 41357332

2. Khan MS, Tomizawa D, Zheng H, Saha V, Ariffin H, Hori H, Arora RS, Tamamyan G, Aisyi M, Kurkure P, Agarwal B, Yu AL, Dalvi R, Kirgizov K, Chen BW, Seksarn P, Nakagawara A, Chan GCF, Arakawa A, Gao Y, Krishnan S, Yeoh AEJ, Luo XQ, Zhu XF, Manabe A, Li CK. Landscape of paediatric oncology clinical trials in Asia. eClinicalMedicine. 2025; Nov 4;89:103555. doi:10.1016/j.eclinm.2025.103555. PMID:41357341

3. Wang N, Tang Y, Zhuang Y, Cai J, Hu S, Yang X, Fang Y, Wu X, Wang N, Wang L, Zhai X, Yang M, Tian X, Wang Y, Li H, Zhao L, Li CK, Chen X, Zhu X. Efficacy of chimeric antigen receptor T-cell therapy in testicular relapse of pediatric acute lymphoblastic leukemia: a multicenter retrospective study. Front Immunol. 2026 Feb 11;17:1766494. doi: 10.3389/fimmu.2026.1766494. eCollection 2026. PMID: 41756298

4. Matino D, Palladino A, Taylor CT, Hwang E, Raje S, Nayak S, McDonald R, Acharya SS, Mahlangu J, Jiménez-Yuste V, Choraria N, Yang R, Li CK, Al-Khabori M, Wali Y, Morales Adrián J, Park YS, Zülfikar OB, J Teeter. Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial. Blood, 2025 Oct 2;146(14):1654-1663. doi: 10.1182/blood.2024027468. PMID: 40608864

5.  Shimamura A, Maschan A, Bennett C, Samarasinghe S, Farrar JE, Li CK, Sirachainan N, Pongtanakul B, Komvilaisak P, Zubarovskaya L, Rothman JA, Walkovich K, Nakano TA, Bertuch AA, Ferrao A, Bhat R, Hanna R, Overholt K, Boklan J, Wong TF, Wang Q, Urban P, Strahm B, Wang W, Vlachos A, Williams DA. Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial. Blood Advances, 2025 Aug 12;9(15):3728-3738. doi: 10.1182/bloodadvances.2024015102. PMID: 40315366

6. Cheung YT, Chan DFY, Lee CK, Tsoi WC, Lau CW, Leung JNS, So JCC, Tsang STY, Wong CLP, Chu YYL, Li CK. Impact of iron deficiency on attention among school-aged adolescents in Hong Kong. Hong Kong Med Journal, 2025; Apr;31(2):139-147. doi: 10.12809/hkmj2310950. PMID: 40201988

7. Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, Zhai X, Liang C, Ju X, Jiang H, Jin R, Wu X, Wang N, Tian X, Pan K, Jiang H, Sun L, Fang Y, Li CK, Hu Q, Yang M, Zhu Y, Zhang H, Li C, Pei D, Jeha S, Yang JJ, Cheng C, Tang J, Zhu X, Pui CH. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2020 Jan 16. doi: 10.1001/jamaoncol.2019.5868.

8. Leung KT, Zhang C, Chan KYY, Li K, Cheung JTK, Ng MHL, Zhang XB, Sit T, Lee WYW, Kang W, To KF, Yu JWS, Man TKF, Wang H, Tsang KS, Cheng FWT, Lam GKS, Chow TW, Leung AWK, Leung TF, Yuen PMP, Ng PC, Li CK.  CD9 blockade suppresses disease progression of high-risk pediatric B-cell precursor acute lymphoblastic leukemia and enhances chemosensitivity.  Leukemia, 2020; 34:709-720.

9. Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, Campbell M, Escherich G, Ferster A, Gardner RA, Kotecha RS, Lausen B, Li CK, Locatelli F, Attarbaschi A, Peters C, Rubnitz JE, Silverman LB, Stary J, Szczepanski T, Vora A, Schrappe M, Valsecchi MG. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol. 2019 Sep 1;37(25):2246-2256.

10. Cui L, Li ZG, Chai YH, Yu J, Gao J, Zhu XF, Jin RM, Shi XD, Zhang LP, Gao YJ, Zhang RD, Zheng HY, Hu SY, Cui YH, Zhu YP, Zou Y, Ng MHL, Xiao Y, Li JH, Zhang YH, He HL, Xian Y, Wang TY, Li CK, Wu MY; Chinese Children Leukemia Group(CCLG). Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China. Am J Hematol. 2018 Apr 20. doi: 10.1002/ajh.25124.

bottom of page